What is the treatment for Clostridium difficile (C. diff) colitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Clostridium difficile Colitis

For initial C. difficile infection, oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days are the first-line treatments, with metronidazole relegated to situations where access to these agents is limited and only for non-severe disease. 1, 2, 3

Disease Severity Classification

Before initiating treatment, classify disease severity using objective criteria:

  • Non-severe CDI: White blood cell count ≤15,000 cells/mL AND serum creatinine <1.5 mg/dL 2, 3
  • Severe CDI: White blood cell count ≥15,000 cells/mL OR serum creatinine ≥1.5 mg/dL 1, 2
  • Fulminant CDI: Hypotension, shock, ileus, toxic megacolon, or acute abdomen 2, 3

Additional markers of severe disease include marked left shift (>20% band neutrophils), elevated serum lactate, pseudomembranous colitis on endoscopy, colonic wall thickening on imaging, or pericolonic fat stranding 1

Initial Episode Treatment by Severity

Non-Severe Disease

First-line options (choose one):

  • Oral vancomycin 125 mg four times daily for 10 days 1, 2
  • Fidaxomicin 200 mg twice daily for 10 days 1, 4
  • Metronidazole 500 mg three times daily for 10 days only if vancomycin and fidaxomicin are unavailable 1, 2

Fidaxomicin offers lower recurrence rates compared to vancomycin (particularly for non-027 ribotypes), making it preferable when available despite higher cost 1, 3, 5

Severe Disease

First-line options (choose one):

  • Oral vancomycin 125 mg four times daily for 10 days 1, 2
  • Fidaxomicin 200 mg twice daily for 10 days 1

Critical point: Vancomycin demonstrated 97% cure rate versus 76% for metronidazole in severe disease 3. Metronidazole use in severe CDI is strongly discouraged 1. Consider increasing vancomycin to 500 mg four times daily for 10 days in severe cases 1

Fulminant Disease

  • High-dose oral vancomycin 500 mg four times daily 2, 3
  • PLUS IV metronidazole 500 mg every 8 hours 2, 3
  • If ileus present, add vancomycin 500 mg via nasogastric tube every 6 hours AND/OR vancomycin retention enema 500 mg in 100 mL normal saline every 4-12 hours 1

There is no evidence supporting fidaxomicin use in life-threatening CDI 1

Recurrent CDI Treatment

First Recurrence

Treat as initial episode unless disease has progressed from non-severe to severe 1. Fidaxomicin 200 mg twice daily for 10 days is preferred due to significantly lower rates of second recurrence (19.7% vs 35.5% with vancomycin) 3, 5

Second and Subsequent Recurrences

Preferred approach:

  • Vancomycin tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then 125 mg twice daily for 7 days, then 125 mg once daily for 7 days, then 125 mg every 2-3 days for 2-8 weeks 1, 3
  • Alternative: Fidaxomicin 200 mg twice daily for 10 days 1

For multiple recurrences unresponsive to antibiotics: Fecal microbiota transplantation in combination with oral antibiotic treatment is strongly recommended after at least 2 recurrences 1, 3

Critical Management Principles

Immediate actions:

  • Discontinue the inciting antibiotic immediately if clinically feasible 2, 3
  • Avoid antiperistaltic agents and opiates as they worsen outcomes and increase complications 1, 3

Monitoring treatment response:

  • Assess clinical response by 72 hours; escalate therapy if no improvement 2
  • Treatment response typically requires 3-5 days 2, 3
  • Do not perform "test of cure" after treatment completion 2, 3

Metronidazole safety concerns:

  • Avoid repeated or prolonged courses due to cumulative and potentially irreversible neurotoxicity risk 2, 3
  • If metronidazole is used and patient shows no improvement by day 3-5, escalate to vancomycin immediately rather than completing the full 10-day course 2

Surgical Intervention

Indications for total abdominal colectomy with ileostomy:

  • Perforation of the colon 1
  • Systemic inflammation with deteriorating clinical condition not responding to antibiotic therapy 1
  • Toxic megacolon, acute abdomen, or severe ileus 1

Timing: Operate before disease becomes very severe; serum lactate >5.0 mmol/L is a marker suggesting surgery should be performed urgently 1

Special Considerations

When oral therapy is impossible (severe ileus):

  • Non-severe: IV metronidazole 500 mg three times daily for 10 days 1
  • Severe: IV metronidazole 500 mg three times daily PLUS vancomycin 500 mg via nasogastric tube every 6 hours AND/OR vancomycin retention enema 500 mg in 100 mL normal saline every 4-12 hours 1

Mild CDI (stool frequency <4 times daily, no signs of severe colitis) clearly induced by antibiotics may be managed by stopping the inducing antibiotic and observing closely for 48 hours, but patients must be placed on therapy immediately if deterioration occurs 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment Approaches for C. difficile Infection by Severity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Clostridioides difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.